CCR10 Modulation for Skin and Intestinal Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The role of CCR10 in regulating immune homeostasis and responses in the skin and intestines remains unclear, and there is a need for effective therapeutics to treat skin and intestinal diseases.

Innovation Solution

Modulating CCR10-associated signals or cells using inhibitors or activators, such as siRNA, microRNA, antisense nucleic acids, or antibodies, to enhance or diminish immune responses in mammals suffering from skin or intestinal diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If CCR10/CCL27 signals are inhibited to treat skin inflammatory diseases, then skin inflammation is reduced, but immune response to infection may be suppressed

Engineering Contradiction:

Improveskin inflammationVSAvoidimmune response to infection

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies inversion by switching between inhibition and activation of CCR10/CCL27 signals depending on the disease state. For inflammatory diseases like psoriasis and dermatitis, CCR10/CCL27 signals are inhibited to reduce inflammation. For infections and cancer, CCR10/CCL27 signals are activated or blocked from inhibition to enhance immune response and improve survival outcomes.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent changes the functional state of CCR10/CCL27 signaling from inhibited to activated based on disease context. This is achieved through parameter changes including using different modulators (antagonists vs agonists), adjusting treatment timing, and modifying the functional state of CCR10+ T cells to achieve therapeutic benefits in different disease conditions.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If CCR10 is blocked to reduce T cell migration in inflamed skin, then skin homing of T cells is reduced, but immune surveillance may be compromised

Engineering Contradiction:

ImproveT cell migration to inflamed skinVSAvoidimmune surveillance

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies local quality by differentiating the functional requirements in different tissue locations. In inflamed skin, CCR10/CCL27 signals are inhibited to reduce harmful T cell migration and inflammation. In non-inflamed tissues and during immune surveillance, CCR10/CCL27 signals are maintained or activated to ensure proper T cell homing and immune protection.

Inventive Principle:

Principle #3Local quality

3Object-affected harmful factors

If CCR10+ T cells are depleted to treat autoimmune diseases, then autoimmune inflammation is reduced, but protection against infection may be diminished

Engineering Contradiction:

Improveautoimmune inflammationVSAvoidprotection against infection

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies dynamics by making CCR10 modulation reversible and adaptable. Rather than permanent depletion, the patent uses dynamic modulation where CCR10/CCL27 signals can be inhibited during autoimmune flares and activated or protected during infection risk periods. This dynamic approach allows the immune system to adapt to changing disease states while maintaining protective functions.

Inventive Principle:

Principle #15Dynamics

Data Source

PatentUS10588941B2Modulation of CCR10 signals for treatment of skin and intestinal inflammatory diseases and infection

Publication Date: 2020.03.17 THE PENN STATE RES FOUND INC

AI summary

The invention provides compositions and methods for targeting CCR10 and/or the CCR10/ligand axis to modulate the immune response in a subject.